Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 3
1995 1
1996 6
1997 2
1998 18
1999 26
2000 38
2001 58
2002 101
2003 122
2004 134
2005 135
2006 111
2007 141
2008 127
2009 126
2010 120
2011 140
2012 148
2013 160
2014 143
2015 165
2016 195
2017 177
2018 162
2019 132
2020 173
2021 171
2022 140
2023 119
2024 41

Text availability

Article attribute

Article type

Publication date

Search Results

2,887 results

Results by year

Filters applied: . Clear all
Page 1
Coronary In-Stent Restenosis: Predictors and Treatment.
Ullrich H, Olschewski M, Münzel T, Gori T. Ullrich H, et al. Dtsch Arztebl Int. 2021 Sep 24;118(38):637-644. doi: 10.3238/arztebl.m2021.0254. Dtsch Arztebl Int. 2021. PMID: 34379053 Free PMC article. Review.
BACKGROUND: Despite the use of modern drug-eluting stents (DES), in-stent restenosis (ISR) may still occur in as many as 2-10% of percutaneous coronary interventions (PCI) in certain lesion/patient subsets. ISR causes increased morbidity after stent implantat …
BACKGROUND: Despite the use of modern drug-eluting stents (DES), in-stent restenosis (ISR) may still occur in as many a …
Drug-Coated Balloon for De Novo Coronary Artery Disease: JACC State-of-the-Art Review.
Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-Garcia HM, Waksman R. Yerasi C, et al. J Am Coll Cardiol. 2020 Mar 10;75(9):1061-1073. doi: 10.1016/j.jacc.2019.12.046. J Am Coll Cardiol. 2020. PMID: 32138967 Free article. Review.
A DCB consists of a semicompliant balloon coated with antiproliferative agents encapsulated in a polymer matrix, which is released into the wall after inflation and contact with the intima. DCB have demonstrated effectiveness in treating in-stent restenosis. …
A DCB consists of a semicompliant balloon coated with antiproliferative agents encapsulated in a polymer matrix, which is released into the …
In-stent Restenosis.
Lee MS, Banka G. Lee MS, et al. Interv Cardiol Clin. 2016 Apr;5(2):211-220. doi: 10.1016/j.iccl.2015.12.006. Epub 2016 Feb 13. Interv Cardiol Clin. 2016. PMID: 28582205 Review.
In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. ...
In-stent restenosis (ISR) is the narrowing of a stented coronary artery lesion. ...
A Randomized Comparison of 2 Different Drug-Coated Balloons for In-Stent Restenosis.
Liu S, Zhou Y, Shen Z, Chen H, Qiu C, Fu G, Li H, Yu Z, Zeng Q, Li Z, Li W, Qiao S; Dissolve ISR Investigators. Liu S, et al. JACC Cardiovasc Interv. 2023 Apr 10;16(7):759-767. doi: 10.1016/j.jcin.2022.12.018. JACC Cardiovasc Interv. 2023. PMID: 37045496 Free article. Clinical Trial.
BACKGROUND: Although use of drug-coated balloons (DCB) is a promising technique, little is known about the clinical efficacy of the Dissolve DCB in drug-eluting stent (DES) in-stent restenosis (ISR). ...However, Dissolve DCB with its numerical increase …
BACKGROUND: Although use of drug-coated balloons (DCB) is a promising technique, little is known about the clinical efficacy of the D …
In-stent restenosis.
Kim MS, Dean LS. Kim MS, et al. Cardiovasc Ther. 2011 Jun;29(3):190-8. doi: 10.1111/j.1755-5922.2010.00155.x. Epub 2010 Apr 9. Cardiovasc Ther. 2011. PMID: 20406239 Free article. Review.
However, despite technological advances and an improved understanding of the restenotic process, the overall rate of in-stent restenosis following bare metal stent implantation remains high. ...The issue of in-stent restenosis (especially …
However, despite technological advances and an improved understanding of the restenotic process, the overall rate of in-stent …
Cardiac allograft vasculopathy.
Lee MS, Finch W, Weisz G, Kirtane AJ. Lee MS, et al. Rev Cardiovasc Med. 2011;12(3):143-52. Rev Cardiovasc Med. 2011. PMID: 22080925 Review.
Although revascularization with PCI has a high immediate success rate, rates of in-stent restenosis are higher as compared with PCI of native coronary arteries, although the advent of drug-eluting stents has somewhat improved in-stent resteno …
Although revascularization with PCI has a high immediate success rate, rates of in-stent restenosis are higher as compa …
Waksman In-Stent Restenosis Classification: A Mechanism-Based Approach to the Treatment of Restenosis.
Shlofmitz E, Case BC, Chen Y, Chezar-Azerrad C, Hashim H, Garcia-Garcia HM, Mintz GS, Waksman R. Shlofmitz E, et al. Cardiovasc Revasc Med. 2021 Dec;33:62-67. doi: 10.1016/j.carrev.2021.06.004. Epub 2021 Jun 5. Cardiovasc Revasc Med. 2021. PMID: 34247983 Review.
Despite contemporary advances in stent technology, in-stent restenosis (ISR) remains a common issue following percutaneous coronary intervention. ...Intravascular imaging with either intravascular ultrasound or optical coherence tomography allows for real-tim …
Despite contemporary advances in stent technology, in-stent restenosis (ISR) remains a common issue following percutane …
Comparison of carotid endarterectomy and repeated carotid angioplasty and stenting for in-stent restenosis (CERCAS trial): a randomised study.
Hrbáč T, Fiedler J, Procházka V, Jonszta T, Roubec M, Pakizer D, Václavík D, Netuka D, Heryán T, Školoudík D. Hrbáč T, et al. Stroke Vasc Neurol. 2023 Oct;8(5):399-404. doi: 10.1136/svn-2022-002075. Epub 2023 Mar 27. Stroke Vasc Neurol. 2023. PMID: 36972920 Free PMC article. Clinical Trial.
BACKGROUND AND AIM: In-stent restenosis (ISR) belongs to an infrequent but potentially serious complication after carotid angioplasty and stenting in patients with severe carotid stenosis. ...CONCLUSION: CEASR seems to be effective and save procedures for pat …
BACKGROUND AND AIM: In-stent restenosis (ISR) belongs to an infrequent but potentially serious complication after carot …
Prevention of Femoropopliteal In-Stent Restenosis With Cilostazol: A Meta-Analysis.
Iftikhar O, Oliveros K, Tafur AJ, Casanegra AI. Iftikhar O, et al. Angiology. 2016 Jul;67(6):549-55. doi: 10.1177/0003319715604768. Epub 2015 Sep 21. Angiology. 2016. PMID: 26390878 Review.
Severe peripheral artery disease requires revascularization to relieve life-limiting ischemic symptoms. Postrevascularization in-stent restenosis continues to be a problem after femoropopliteal procedures. Our aim was to evaluate the use of cilostazol to prev …
Severe peripheral artery disease requires revascularization to relieve life-limiting ischemic symptoms. Postrevascularization in-s …
Safety and efficacy of paclitaxel drug-coated balloon in femoropopliteal in-stent restenosis.
Anantha-Narayanan M, Love K, Nagpal S, Sheikh AB, Regan CJ, Mena-Hurtado C. Anantha-Narayanan M, et al. Expert Rev Med Devices. 2020 Jun;17(6):533-539. doi: 10.1080/17434440.2020.1770593. Epub 2020 Jun 11. Expert Rev Med Devices. 2020. PMID: 32525406 Review.
Self-expanding nitinol stents are now frequently used for the treatment of FP disease but in-stent restenosis (ISR) remains a major issue that can lead to recurrence of symptoms requiring repeated revascularizations. ...EXPERT OPINION: Currently available dat …
Self-expanding nitinol stents are now frequently used for the treatment of FP disease but in-stent restenosis (ISR) rem …
2,887 results